Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation — FDA 510(k) Submissions

Adaptive Biotechnologies Corporation has submitted 2 FDA 510(k) premarket notifications since 2018, of which 1 received clearance as substantially equivalent to a predicate device.

The company's most frequent device categories include Dna-based Test For Minimal Residual Disease For Hematologic Malignancies . Use the specialty filter in the sidebar to narrow results.